Immunotherapy advances for glioblastoma

Survival for patients with glioblastoma, the most common high-grade primary CNS tumor, remains poor despite multiple therapeutic interventions including intensifying cytotoxic therapy, targeting dysregulated cell signaling pathways, and blocking angiogenesis. Exciting, durable clinical benefits have...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Reardon, David A., Freeman, Gordon, Wu, Catherine, Chiocca, E. Antonio, Wucherpfennig, Kai W., Wen, Patrick Y., Fritsch, Edward F., Curry, William T., Sampson, John H., Dranoff, Glenn
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2014
Assuntos:
Reviews
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201077/
https://ncbi.nlm.nih.gov/pubmed/25190673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou212
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares